Scarica l'app Stockscreener
40.45
6.20%
2.36
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$38.09
Aprire:
$38.01
Volume 24 ore:
3.51M
Relative Volume:
1.56
Capitalizzazione di mercato:
$5.59B
Reddito:
$181.74M
Utile/perdita netta:
$-143.97M
Rapporto P/E:
-29.10
EPS:
-1.39
Flusso di cassa netto:
$9.60M
1 W Prestazione:
-1.96%
1M Prestazione:
+6.36%
6M Prestazione:
+164.21%
1 anno Prestazione:
+121.28%
Intervallo 1D:
$37.43
$40.58
Intervallo di 1 settimana:
$37.06
$43.59
Portata 52W:
$9.57
$43.69
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Nome
Arrowhead Pharmaceuticals Inc
Settore
Industria
Telefono
626-696-4702
Indirizzo
177 E COLORADO BLVD, PASADENA, CA
Confronta ARWR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
40.45 | 5.27B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-05 | Iniziato | Goldman | Neutral |
| 2023-12-04 | Iniziato | BofA Securities | Buy |
| 2023-09-19 | Iniziato | Citigroup | Neutral |
| 2023-07-21 | Iniziato | TD Cowen | Outperform |
| 2023-05-12 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Iniziato | SMBC Nikko | Outperform |
| 2023-04-12 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Ripresa | Goldman | Buy |
| 2021-08-06 | Reiterato | Chardan Capital Markets | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-19 | Iniziato | Citigroup | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-05-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Iniziato | Goldman | Neutral |
| 2020-01-21 | Iniziato | SVB Leerink | Underperform |
| 2019-12-13 | Iniziato | Oppenheimer | Perform |
| 2019-11-29 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-27 | Reiterato | B. Riley FBR | Buy |
| 2019-11-25 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Reiterato | Chardan Capital Markets | Buy |
| 2019-10-03 | Iniziato | Robert W. Baird | Outperform |
| 2018-09-07 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-08-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
Goldman Sachs Reaffirms Their Hold Rating on Arrowhead Pharmaceuticals (ARWR) - The Globe and Mail
Analyzing Arrowhead Pharmaceuticals After Doubling in Price With RNA Therapy Breakthroughs - Yahoo Finance
A Look at Arrowhead Pharmaceuticals’s Valuation Following FDA Approval of First siRNA Therapy for Rare Disease - Yahoo Finance
How Analyst Views Are Shifting as Arrowhead Pharmaceuticals Enters a New Phase of Growth - Yahoo Finance
Arrowhead rises as FDA approves lead drug for rare disorder - MSN
Arrowhead Pharma (ARWR): Analyst Rating Update on November 20, 2 - GuruFocus
How supply chain issues affect Arrowhead Pharmaceuticals Inc. stockSwing Trade & Trade Opportunity Analysis - newser.com
Is Arrowhead Pharmaceuticals Inc. (HDP1) stock supported by free cash flow2025 Institutional Moves & Consistent Growth Stock Picks - newser.com
Arrowhead Pharma stock price target raised to $70 from $45 at Piper Sandler - Investing.com Canada
What macro factors could drive Arrowhead Pharmaceuticals Inc. (HDP1) stock higherDay Trade & AI Enhanced Execution Alerts - newser.com
Arrowhead Pharma stock gets Buy rating reaffirmed by H.C. Wainwright - Investing.com Canada
RBC Capital Maintains Arrowhead Pharmaceuticals (ARWR) Outperform Recommendation - Nasdaq
Arrowhead’s Redemplo Approval Sets Up Standoff With Ionis’s Tryngolza - Citeline News & Insights
How Arrowhead Pharmaceuticals Inc. (HDP1) stock reacts to Fed tighteningIPO Watch & Long-Term Capital Growth Strategies - newser.com
Will Arrowhead Pharmaceuticals Inc. stock continue dividend increases2025 Year in Review & Momentum Based Trading Ideas - newser.com
ARWR: REDEMPLO Approved by FDA for the Treatment of FCS - Smartkarma
Arrowhead nets first commercial win as siRNA drug garners FDA approval - Yahoo Finance
Can Arrowhead Pharmaceuticals Inc. stock hit analyst price targetsOptions Play & Consistent Profit Focused Trading Strategies - newser.com
Arrowhead Pharmaceuticals Steps Into The Rare Disease Market - Finimize
Arrowhead Pharmaceuticals Poised for Commercial Transition After First FDA Approval, RBC Says - MarketScreener
ARWR: RBC Capital Raises Price Target and Maintains Outperform Rating | ARWR Stock News - GuruFocus
Arrowhead Pharma stock price target raised by RBC to $52 on Redemplo approval - Investing.com Canada
Arrowhead Pharma stock rises as FDA approves Redemplo for FCS treatment - Investing.com Canada
Arrowhead Pharma stock holds steady as Cantor Fitzgerald reiterates Overweight rating - Investing.com Canada
What dividend safety rating applies to Arrowhead Pharmaceuticals Inc. (HDP1) stockMarket Sentiment Report & Weekly Top Performers Watchlists - newser.com
ARWR: Chardan Capital Maintains Buy Rating and $60 Price Target - GuruFocus
Piper Sandler Raises ARWR Price Target to $70.00 | ARWR Stock Ne - GuruFocus
Trend analysis for Arrowhead Pharmaceuticals Inc. this weekWeekly Market Summary & Free Safe Entry Trade Signal Reports - newser.com
Will Arrowhead Pharmaceuticals Inc. stock benefit from upcoming earnings reportsMarket Sentiment Report & Real-Time Volume Analysis - newser.com
FDA nod for Arrowhead’s Redemplo in FCS - The Pharma Letter
Why Arrowhead Pharmaceuticals Inc. (HDP1) stock signals breakout potential - newser.com
How Arrowhead Pharmaceuticals Inc. (HDP1) stock behaves under inflation pressureWeekly Earnings Recap & Low Risk High Reward Ideas - newser.com
Will Arrowhead Pharmaceuticals Inc. stock gain from lower inflationMarket Sentiment Review & Free Technical Pattern Based Buy Signals - newser.com
Arrowhead Is A Buy On REDEMPLO(TM) Approval And Strong Cash Runway - Seeking Alpha
Arrowhead Pharmaceuticals’ REDEMPLO Approved by FDA - MSN
With FDA Approval for RNAi Drug, Arrowhead Pharma Starts Price War With Rival Ionis - MedCity News
Risk vs reward if holding onto Arrowhead Pharmaceuticals Inc.2025 Top Gainers & Fast Moving Stock Trade Plans - newser.com
Arrowhead Pharmaceuticals(ARWR) Stock: Climbs Following FDA Approval of REDEMPLO for Rare Disease Treatment - parameter.io
Arrowhead Secures Maiden Approval, First FDA Nod for Rare Genetic Metabolic Disorder - BioSpace
Arrowhead Just Won FDA Approval, But the Math Tells a Different Story - CTOL Digital Solutions
US FDA approves Arrowhead's genetic disorder drug - Reuters
Arrowhead’s plozasiran cleared for FCS; Ionis patent duel awaits - BioWorld MedTech
RNAi biotech Arrowhead wins first FDA approval - BioPharma Dive
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® - TradingView
Arrowhead Pharmaceuticals Inc Azioni (ARWR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):